Report for: Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial

Title	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial
Published in	Trials, May 2021
DOI	10.1186/s13063-021-05231-7
Pubmed ID	33947444
Authors	Deonna M. Ackermann, Amelia K. Smit, Monika Janda, Cathelijne H. van Kemenade, Mbathio Dieng, Rachael L. Morton, Robin M. Turner, Anne E. Cust, Les Irwig, Jolyn K. Hersch, Pascale Guitera, H. Peter Soyer, Victoria Mar, Robyn P. M. Saw, Donald Low, Cynthia Low, Dorothy Drabarek, David Espinoza, Jon Emery, Peter Murchie, John F. Thompson, Richard A. Scolyer, Anthony Azzi, Alister Lilleyman, Katy J. L. Bell

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Unknown	1	100%

Type	Count	As %
Members of the public	1	100%

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	43	100%

Readers by professional status	Count	As %
Student > Bachelor	6	14%
Student > Ph. D. Student	5	12%
Other	3	7%
Researcher	2	5%
Professor	2	5%
Other	3	7%
Unknown	22	51%

Readers by discipline	Count	As %
Medicine and Dentistry	7	16%
Nursing and Health Professions	3	7%
Psychology	3	7%
Economics, Econometrics and Finance	2	5%
Business, Management and Accounting	1	2%
Other	4	9%
Unknown	23	53%

Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial